INTRODUCTION: Contract research organization (CRO) support is largely included in clinical trial management, although its effect in terms of time savings and benefit has not yet been quantified. We performed a retrospective multicenter analysis of lung cancer trials to explore differences in term of trial activation timelines and accrual for studies with and without CRO involvement. MATERIALS AND METHODS: Results regarding study timelines from feasibility data to first patient enrollment were collected from 7 Italian thoracic oncology departments. The final accruals (screened/enrolled patients) are reported. We considered CRO/sponsor-administered and CRO-free trials according to who was responsible for the management of the crucial setup p...
Background The time from a referral for suspected lung cancer is received at a hospital until treatm...
OBJECTIVE: Surgery for early stage non-small cell lung cancer can be curative. A delay from diagnosi...
ObjectivesAfter regulatory approval, drug companies, public funding agencies and academic researcher...
Although contract research organization (CRO) support is commonly included in clinical trial managem...
Aim: The aim of this paper is to describe the time spent to activate oncological non-profit clinical...
AIM: The aim of this paper is to describe the time spent to activate oncological non-profit clinical...
Objectives: The recent success of individualized lung cancer therapy has triggered fundamental chang...
Background: During recent years, the burden of bureaucracy in clinical research has increased dramat...
Objectives: Diagnostic assessment programs (DAPs) can reduce wait times for cancer diagnosis but opt...
ObjectiveTo examine factors associated with accrual rate in industry sponsored clinical trials suppo...
Background:Minimizing the time until start of cancer treatment is a political goal. In Norway, the t...
Pharmaceutical, biotechnology and medical device companies hire contract research organizations (CRO...
Very little is known about the proportion of oncology trials that get published, the time it takes t...
Background: Clinical trials represent a significant percentage of the time and cost to bring a drug ...
PURPOSE: Community-based research programs face many barriers to participation in clinical trials. A...
Background The time from a referral for suspected lung cancer is received at a hospital until treatm...
OBJECTIVE: Surgery for early stage non-small cell lung cancer can be curative. A delay from diagnosi...
ObjectivesAfter regulatory approval, drug companies, public funding agencies and academic researcher...
Although contract research organization (CRO) support is commonly included in clinical trial managem...
Aim: The aim of this paper is to describe the time spent to activate oncological non-profit clinical...
AIM: The aim of this paper is to describe the time spent to activate oncological non-profit clinical...
Objectives: The recent success of individualized lung cancer therapy has triggered fundamental chang...
Background: During recent years, the burden of bureaucracy in clinical research has increased dramat...
Objectives: Diagnostic assessment programs (DAPs) can reduce wait times for cancer diagnosis but opt...
ObjectiveTo examine factors associated with accrual rate in industry sponsored clinical trials suppo...
Background:Minimizing the time until start of cancer treatment is a political goal. In Norway, the t...
Pharmaceutical, biotechnology and medical device companies hire contract research organizations (CRO...
Very little is known about the proportion of oncology trials that get published, the time it takes t...
Background: Clinical trials represent a significant percentage of the time and cost to bring a drug ...
PURPOSE: Community-based research programs face many barriers to participation in clinical trials. A...
Background The time from a referral for suspected lung cancer is received at a hospital until treatm...
OBJECTIVE: Surgery for early stage non-small cell lung cancer can be curative. A delay from diagnosi...
ObjectivesAfter regulatory approval, drug companies, public funding agencies and academic researcher...